Business
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the pricing of its initial public offering of 3,375,000 shares of common stock at a price of $4.00 per share. The gross proceeds to Apimeds from the
About this update from Apimeds Pharmaceuticals Us, Inc.
[{"type":"text","content":"Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the pricing of its initial public offering of 3,375,000 shares of common stock at a price of $4.00 per share.","length":461,"tagName":"p"},{"type":"text","content":"The gross proceeds to Apimeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, are expected to be $13.5 million. In addition, the Company has granted the underwriters a 45-day option from the closing of the offering to purchase up to an additional 506,250 shares of common stock at the public offering price, less underwriting discounts, and issued to the underwriters warrants to purchase up to a total of 168,750 shares of common stock (or 194,063 shares if the over-allotment option is exercised in full) exercisable during the four and a half-year period commencing 180 days from the closing of the offering. The offering is expected to close on May 12, 2025, subject to the satisfaction of customary closing conditions. The shares are expected to begin trading on the NYSE American on May 9, 2025, under the symbol “APUS.”D. Boral Capital LLC is acting as sole book-running manager for the offering.","length":984,"tagName":"p"},{"type":"text","content":"The Company expects to use the net proceeds from the sale of the shares to fund a Phase III clinical trial in knee osteoarthritis, to initiate at least one non-registered corporate sponsorship study in multiple sclerosis, to manufacture its product candidate, and to address general working capital needs.A registration statement on Form S-1 (File No. 333-282324) relating to the securities being sold in this offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on February 11, 2025. A post-effective amendment to the registration statement was filed with the SEC and declared effective on May 5, 2025. This offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained, when available, from: D. Boral ...